[go: up one dir, main page]

AU1062595A - Means and method for hormonal contraception and/or acne treatment - Google Patents

Means and method for hormonal contraception and/or acne treatment

Info

Publication number
AU1062595A
AU1062595A AU10625/95A AU1062595A AU1062595A AU 1062595 A AU1062595 A AU 1062595A AU 10625/95 A AU10625/95 A AU 10625/95A AU 1062595 A AU1062595 A AU 1062595A AU 1062595 A AU1062595 A AU 1062595A
Authority
AU
Australia
Prior art keywords
hormonal
daily
units
hormonal component
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU10625/95A
Other versions
AU703064B2 (en
Inventor
Marika Ehrlich
Herbert Kuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU1062595A publication Critical patent/AU1062595A/en
Application granted granted Critical
Publication of AU703064B2 publication Critical patent/AU703064B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method for hormonal contraception having a first hormonal component and a second hormonal component packaged separately in a packing unit and intended for short-term sequential administration, each of the hormonal components being composed of a plurality of daily hormone units separately packaged and individually removable in the packing unit. The first hormonal component contains almost exclusively an estrogen preparation as an active hormonal ingredient, effecting a disturbance of the follicle stimulation. The second hormonal component contains, in combination, an estrogen preparation and a progestogen preparation in a therapeutic amount sufficient for ovulation inhibition. The total number of daily hormone units is equal to the total number of days of the desired cycle, with the first hormonal component including 5 or 14 daily units and the second hormonal component including 23 or 14 daily units. The plurality of daily units of the first hormonal component is lower than the plurality of daily units of the second hormonal component, characterized by such an arrangement of the daily units in the packaging unit that the daily units of the second hormonal component are taken first and the daily units of the first hormonal component are taken thereafter. The daily units of the second hormonal component do not contain the combination of biologically produced estrogen and synthetic estrogen.
AU10625/95A 1993-12-24 1994-11-24 Means and method for hormonal contraception and/or acne treatment Ceased AU703064B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4344405 1993-12-24
DE4344405A DE4344405C2 (en) 1993-12-24 1993-12-24 Anti-ovulation agent and method for hormonal contraception
PCT/DE1994/001420 WO1995017895A1 (en) 1993-12-24 1994-11-24 Means and method for hormonal contraception and/or the treatment of acne

Publications (2)

Publication Number Publication Date
AU1062595A true AU1062595A (en) 1995-07-17
AU703064B2 AU703064B2 (en) 1999-03-11

Family

ID=6506160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10625/95A Ceased AU703064B2 (en) 1993-12-24 1994-11-24 Means and method for hormonal contraception and/or acne treatment

Country Status (20)

Country Link
US (1) US5662927A (en)
EP (1) EP0735881B1 (en)
JP (1) JPH09502733A (en)
KR (1) KR960706344A (en)
AT (1) ATE247969T1 (en)
AU (1) AU703064B2 (en)
BG (1) BG62597B1 (en)
BR (1) BR9408513A (en)
CA (1) CA2179422A1 (en)
CZ (1) CZ186096A3 (en)
DE (2) DE4344405C2 (en)
ES (1) ES2206487T3 (en)
FI (1) FI962559A7 (en)
HU (1) HUT74428A (en)
NO (1) NO309843B1 (en)
NZ (1) NZ276370A (en)
PL (1) PL182544B1 (en)
RU (1) RU2169566C2 (en)
SK (1) SK79596A3 (en)
WO (1) WO1995017895A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (en) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component
DE19513662A1 (en) * 1995-04-08 1996-10-10 Schering Ag Combined pharmaceutical preparation for hormonal contraception
DE19525017A1 (en) 1995-06-28 1997-01-02 Schering Ag Pharmaceutical combination preparation, kit and method for hormonal contraception
DE19531936A1 (en) * 1995-08-17 1997-02-20 Schering Ag Combination preparation for contraception, containing kits and a method using them
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
US7871995B2 (en) 2001-05-23 2011-01-18 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2002094279A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
PT1293210E (en) * 2001-05-23 2004-04-30 Pantarhei Bioscience Bv DEVICE AND HORMONAL ANTICONCEPTIONAL METHOD
CA2467222C (en) * 2001-11-15 2010-06-08 Herman Jan Tijmen Coelingh Bennink Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
IL162182A0 (en) * 2001-12-05 2005-11-20 Barr Lab Inc Kits containing oral contraceptives and methods utilizing the same
WO2003103685A1 (en) 2002-06-11 2003-12-18 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
CN1691947B (en) 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 Application of estrogen component in preparation for treatment or prevention of immune-mediated diseases and pharmaceutical composition comprising said estrogen component
EP1526856B1 (en) 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
ES2298570T3 (en) 2002-10-23 2008-05-16 Pantarhei Bioscience B.V. PHARMACEUTICAL COMPOSITIONS THAT INCLUDE STETROL DERIVATIVES FOR USE IN CANCER THERAPY.
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
RU2252014C1 (en) * 2003-12-23 2005-05-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Method for choosing therapy in case of acne
EP1550447A1 (en) * 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstrual cycle control and improvement of conception rates in females
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
CN101583363B (en) 2007-01-08 2013-08-21 潘塔希生物科学股份有限公司 Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN107787224A (en) 2015-06-18 2018-03-09 密特拉制药公司 Orodispersible dosage unit containing estetrol component
PL3106148T3 (en) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodispersible dosage unit containing an estetrol component
CN107810001A (en) 2015-06-18 2018-03-16 密特拉制药公司 Orodispersible tablets containing estetrol
CA2988362C (en) 2015-06-18 2022-07-19 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
WO2019154899A1 (en) 2018-02-07 2019-08-15 Estetra Sprl Contraceptive composition with reduced cardiovascular effects
JOP20200260A1 (en) 2018-04-19 2019-10-19 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
TWI801561B (en) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 Compounds and their uses for alleviating menopause-associated symptoms
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
TWI893101B (en) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 Contraceptive compositions with reduced adverse effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733407A (en) * 1971-08-25 1973-05-15 Syntex Corp Menopause treatment
US4183924A (en) * 1978-02-27 1980-01-15 Schering Corporation 17α-Chloro-17β-hydrocarbonsulfinyl-1,4-androstadienes and the corresponding 17β-hydrocarbonsulfonyl derivatives and their use as anti-acne agents
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
DE4104385C1 (en) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4308406C1 (en) * 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4313926A1 (en) * 1993-04-28 1994-11-03 Jenapharm Gmbh Multiphase pharmaceutical product for hormonal contraception

Also Published As

Publication number Publication date
NO962663L (en) 1996-08-21
DE4344405C2 (en) 1995-12-07
BG100671A (en) 1997-04-30
DE4344405A1 (en) 1995-06-29
SK79596A3 (en) 1997-01-08
PL182544B1 (en) 2002-01-31
WO1995017895A1 (en) 1995-07-06
HUT74428A (en) 1996-12-30
EP0735881A1 (en) 1996-10-09
CZ186096A3 (en) 1997-06-11
NO962663D0 (en) 1996-06-21
FI962559A0 (en) 1996-06-19
ATE247969T1 (en) 2003-09-15
DE59410318D1 (en) 2003-10-02
US5662927A (en) 1997-09-02
FI962559A7 (en) 1996-06-19
CA2179422A1 (en) 1995-07-06
EP0735881B1 (en) 2003-08-27
KR960706344A (en) 1996-12-09
BR9408513A (en) 1997-08-19
PL315119A1 (en) 1996-10-14
NZ276370A (en) 1997-06-24
ES2206487T3 (en) 2004-05-16
NO309843B1 (en) 2001-04-09
RU2169566C2 (en) 2001-06-27
AU703064B2 (en) 1999-03-11
HU9601714D0 (en) 1996-08-28
BG62597B1 (en) 2000-03-31
JPH09502733A (en) 1997-03-18

Similar Documents

Publication Publication Date Title
AU1062595A (en) Means and method for hormonal contraception and/or acne treatment
AU5053896A (en) Ovulation-inhibiting means for hormonal contraception
IL92069A0 (en) Contraception system and method
DE69710896D1 (en) Progestogen-anti-progestogen therapien
UA41401C2 (en) Pharmaceutical combined contraceptive agent
ZA965547B (en) Pharmaceutical combination preparation kit and hormonal contraception method
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
WO1994002103A3 (en) Ovulation inhibitor for hormonal contraception
AU695894B2 (en) Hormonal means for acne therapy and employment thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired